Excitingly, agonists of the Nrf2 signaling pathway, DMF, have entered the clinical study phase for the treatment of patients with pulmonary hypertension caused by systemic sclerosis (SSc) [96]. Here, NFE2L2 is linked to pulmonary hypertension.